QBIO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 bal. 2024 @ 21:32):

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies...

Stats
Šios dienos apimtis	1 123.00
Vidutinė apimtis	23 222.00
Rinkos kapitalizacija	29 019.00
EPS	$0 ( 2024-03-13 )
Kita pelno data	( $0 ) 2024-05-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-05-26	Corin Denis	Buy	200 000	Common Stock
2021-02-01	Rosenstadt William S	Buy	35 000	Common stock
2020-10-27	Corin Denis	Buy	500 000	Incentive Stock Options
2020-08-29	Corin Denis	Buy	150 000	Incentive Stock Options
2020-08-29	Corin Denis	Buy	150 000	Incentive Stock Options

INSIDER POWER
100.00
Last 100 transactions
Buy: 7 488 702 \| Sell: 150 251

Q BioMed Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Q BioMed Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	$284 352
Bruto pelnas:	$-8 988.00 (-3.16 %)
EPS:	$-0.0160

FY	2022
Pajamos:	$284 352
Bruto pelnas:	$-8 988.00 (-3.16 %)
EPS:	$-0.0160

FY	2021
Pajamos:	$195 597
Bruto pelnas:	$-51 249.00 (-26.20 %)
EPS:	$-0.298

FY	2020
Pajamos:	$30 000.00
Bruto pelnas:	$-296 009 (-986.70 %)
EPS:	$-0.650

Financial Reports:

No articles found.

Q BioMed Inc.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.